“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.
|Articles|July 1, 2008
Oncology NEWS International
- Oncology NEWS International Vol 17 No 7
- Volume 17
- Issue 7
p110-Beta Drives Cancer Growth When PTEN is Inhibited, Animal Study Shows
Mice that are prone to develop prostate tumors because they lack the PTEN tumor-suppressor protein remained cancer free when researchers disabled the growth-stimulating p110-beta protein, suggesting that this protein could be a promising prostate cancer drug target (Nature doi:10.1038/nature07091).
Advertisement
Mice that are prone to develop prostate tumors because they lack the PTEN tumor-suppressor protein remained cancer free when researchers disabled the growth-stimulating p110-beta protein, suggesting that this protein could be a promising prostate cancer drug target (Nature doi:10.1038/nature07091).
“The surprise is that p110-beta has been found to be a bigger player than p110-alpha in tumors that result from PTEN loss,” said Jean Zhao, PhD, of Dana-Farber Cancer Institute. “Now the drug companies that have been focusing on p110-alpha, will have to think about making p110-beta inhibitors as well.” The authors speculate that p110-beta may be providing a low-level but steady growth stimulus, and when PTEN is lost, it becomes an important source of cell proliferation signals.
Articles in this issue
about 18 years ago
National Cancer Survivors Dayover 18 years ago
New Indication for Velcade in Previously Untreated Myelomaover 18 years ago
Risk Factors for Mantle Cell Lymphoma Identifiedover 18 years ago
RAS Mutations Enhance Chemotherapy in AMLover 18 years ago
Antidiabetic Agent Metformin May Boost pCRs in Breast Caover 18 years ago
Eisai Seeks Full FDA Approval for Ontak for CTCLover 18 years ago
Symptom Screen Plus CA125 Detects Early Ovarian Caover 18 years ago
Cisplatin Linked to Cardiac Complications in Testicular Ca Patientsover 18 years ago
Updated X-ACT Study Results Presentedover 18 years ago
ThromboGenics and BioInvent Announce Alliance with RocheAdvertisement
Related to this article
At 8 years, SBRT and radical prostatectomy had similar disease control in the PACE-A trial, with less urinary incontinence after SBRT.
“When we give the most effective therapy at the time of new diagnosis, we get the most value out of the effort and time that we and our patients are spending,” said Neeraj Agarwal, MD, FASCO.
An aglatimagene besadenovec-based radiotherapy combination increased intratumoral lymphocyte fraction in intermediate- to high-risk localized prostate cancer.
“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.
In a secondary analysis of the DEPROMP trial, 94.8% of biopsy-naive men had no AEs immediately after multimodal MRI- and PSMA PET/CT–guided prostate biopsy.
The FDA cleared the SpaceOAR Flex System, a hydrogel spacer used during prostate cancer radiotherapy, in a 510(k) supported by the HYDROSPACE trial.
“Cardiovascular assessment should begin when the patient is being selected for treatment, not after the toxicity emerges,” said Faisal Mehmud, MD, MRCP.
Advertisement
Advertisement
Trending on CancerNetwork
1
What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?
2
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
3
CARTITUDE-2 Cohort A Follow-Up Data and Preparing Patients for CAR TCell Therapy
4
Ciltacabtagene Autoleucel Manufacturing, Debulking, and Bridging in Multiple Myeloma
5